Interim Clinical Commissioning Policy: Neutralising monoclonal antibodies and intravenous antivirals in the treatment of COVID-19 in hospitalised patients

Document first published:
Page updated:
Topic:
,
Publication type:

Neutralising monoclonal antibodies or intravenous antivirals are recommended to be available as a treatment option for COVID-19 through routine commissioning for adults and children (aged 12 years and above) patients in hospital with COVID-19 infection in accordance with the criteria set out in this document.

Summary

Published 31 January 2022.

Effective from 10 February 2022.

Summary

Published 31 January 2022.

Effective from 10 February 2022.

Summary

Published 31 January 2022.

Effective from 10 February 2022.